Sjogren's Syndrome - Pipeline Review, H2 2014

Date: December 31, 2014
Pages: 55
Price:
US$ 2,000.00 US$ 1,600.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: SEF05D74100EN
Leaflet:

Download PDF Leaflet

Sjogren's Syndrome - Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Sjogren's Syndrome - Pipeline Review, H2 2014’, provides an overview of the Sjogren's Syndrome’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Sjogren's Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sjogren's Syndrome and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Sjogren's Syndrome
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Sjogren's Syndrome and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Sjogren's Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Sjogren's Syndrome pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Sjogren's Syndrome
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Sjogren's Syndrome pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Sjogren's Syndrome Overview
Therapeutics Development
Pipeline Products for Sjogren's Syndrome - Overview
Pipeline Products for Sjogren's Syndrome - Comparative Analysis
Sjogren's Syndrome - Therapeutics under Development by Companies
Sjogren's Syndrome - Therapeutics under Investigation by Universities/Institutes
Sjogren's Syndrome - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Sjogren's Syndrome - Products under Development by Companies
Sjogren's Syndrome - Products under Investigation by Universities/Institutes
Sjogren's Syndrome - Companies Involved in Therapeutics Development
Bristol-Myers Squibb Company
MedImmune, LLC
Novartis AG
Takeda Pharmaceutical Company Limited
Toleranzia AB
Sjogren's Syndrome - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
abatacept (recombinant) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ABS-11 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy for Type 1 Diabetes and Sjogrens Syndrome - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CFZ-533 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IMSO-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MEDI-4920 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MLN-3126 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NS2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein for Sjogren's Syndrome - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein to Antagonize LTB4 and C5 for Respiratory, Immunological, CNS and Hematological Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VAY-736 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sjogren's Syndrome - Recent Pipeline Updates
Sjogren's Syndrome - Dormant Projects
Sjogren's Syndrome - Discontinued Products
Sjogren's Syndrome - Product Development Milestones
Featured News & Press Releases
Dec 16, 2014: Aldeyra Therapeutics Abstract Accepted at 2015 American Academy of Allergy Asthma & Immunology Annual Meeting
Apr 22, 2011: Breakthrough study links Type 1 diabetes and Sjogren’s syndrome
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Sjogren's Syndrome, H2 2014
Number of Products under Development for Sjogren's Syndrome - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
umber of Products under Investigation by Universities/Institutes, H2 2014
Comparative Analysis by Late Stage Development, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Comparative Analysis by Early Stage Development, H2 2014
Products under Development by Companies, H2 2014
Products under Investigation by Universities/Institutes, H2 2014
Sjogren's Syndrome - Pipeline by Bristol-Myers Squibb Company, H2 2014
Sjogren's Syndrome - Pipeline by MedImmune, LLC, H2 2014
Sjogren's Syndrome - Pipeline by Novartis AG, H2 2014
Sjogren's Syndrome - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014
Sjogren's Syndrome - Pipeline by Toleranzia AB, H2 2014
Assessment by Monotherapy Products, H2 2014
Number of Products by Stage and Target, H2 2014
Number of Products by Stage and Mechanism of Action, H2 2014
Number of Products by Stage and Route of Administration, H2 2014
Number of Products by Stage and Molecule Type, H2 2014
Sjogren's Syndrome Therapeutics - Recent Pipeline Updates, H2 2014
Sjogren's Syndrome - Dormant Projects, H2 2014
Sjogren's Syndrome - Discontinued Products, H2 2014

LIST OF FIGURES

Number of Products under Development for Sjogren's Syndrome, H2 2014
Number of Products under Development for Sjogren's Syndrome - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Comparative Analysis by Early Stage Products, H2 2014
Assessment by Monotherapy Products, H2 2014
Number of Products by Top 10 Targets, H2 2014
Number of Products by Stage and Top 10 Targets, H2 2014
Number of Products by Top 10 Mechanism of Actions, H2 2014
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014
Number of Products by Top 10 Routes of Administration, H2 2014
Number of Products by Stage and Top 10 Routes of Administration, H2 2014
Number of Products by Top 10 Molecule Types, H2 2014
Number of Products by Stage and Top 10 Molecule Types, H2 2014

COMPANIES MENTIONED

Bristol-Myers Squibb Company
MedImmune, LLC
Novartis AG
Takeda Pharmaceutical Company Limited
Toleranzia AB
Skip to top


Ask Your Question

Sjogren's Syndrome - Pipeline Review, H2 2014
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: